Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent
Liuyan Jiang
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorSunny Malik
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorMark Litzow
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorDennis Gastineau
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorIvana Micallef
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorVivek Roy
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorLawrence Solberg
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorCorresponding Author
Abba C. Zubair
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Abba Zubair, MD, PhD, Assistant Professor, Division of Laboratory Medicine and Pathology, 4500 San Pablo Road South, Jacksonville, FL 32224; e-mail: [email protected].Search for more papers by this authorLiuyan Jiang
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorSunny Malik
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorMark Litzow
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorDennis Gastineau
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorIvana Micallef
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorVivek Roy
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorLawrence Solberg
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Search for more papers by this authorCorresponding Author
Abba C. Zubair
From the Department of Laboratory Medicine and Pathology and the Division of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, Florida; and the Division of Hematology-Oncology, Mayo Clinic Rochester, Rochester, Minnesota.
Abba Zubair, MD, PhD, Assistant Professor, Division of Laboratory Medicine and Pathology, 4500 San Pablo Road South, Jacksonville, FL 32224; e-mail: [email protected].Search for more papers by this authorFunded by the National Cancer Institute, NIH Grant CA102824.
Abstract
BACKGROUND: Marrow damage from chemo- and radiation therapies has been suggested to affect quality and quantity of hematopoietic stem cell (HSC) products. We tested the hypothesis that CD34+ cells (HSCs) from low mobilizers are qualitatively inferior to HSCs from high mobilizers.
STUDY DESIGN AND METHODS: HSC quality was defined by proportion of primitive HSC subsets (CD34+CD38−, CD34+HLA-DR−, and CD34+ in G0 stage of cell cycle), the proportion of HSCs that express CXCR4 and CD26 homing proteins, and days to neutrophil and platelet (PLT) engraftments after transplant. HSC content and CD34 subsets analyses were performed using flow cytometry following the ISHAGE protocol. We evaluated the HSC quantity and quality of 139 autologous filgrastim-mobilized HSC products. Patients were categorized into low, moderate, and high mobilizers if their total HSC collection was less than 3 × 106, 3 × 106 or more and less than 5 × 106, and 5 × 106/kg or more, respectively.
RESULTS: The median number of primitive CD34 subsets increases with increasing HSC numbers and this association was significant (p = 0.001). However, when the ratios of the primitive CD34 subsets to total HSC counts were compared among the mobilization groups, the ratios were not significantly different. Coexpression of neither CD26 nor CXCR4 with CD34 antigen correlated with HSC mobilization. Evaluation of days to neutrophil engraftment among the mobilization groups did not show a significant difference (p = 0.1). However, days to PLT engraftment among the mobilization groups was significantly different (p = 0.05).
CONCLUSION: The quality of HSCs from low mobilizers was comparable to HSCs from high mobilizers.
REFERENCES
- 1 Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181-95.
- 2 Fruehauf S, Haas R, Zeller WJ, Hunstein W. CD34 selection for purging in multiple myeloma and analysis of CD34+ B cell precursors. Stem Cells 1994; 12: 95-102.
- 3 Sutherland DR, Keating A, Nayar R, Anania S, Stewart AK. Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol 1994; 22: 1003-10.
- 4 Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M, Samstein RM, Goichberg P, Spiegel A, Elson A, Lapidot T. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006; 12: 657-64.
- 5 Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-9.
- 6 Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-37.
- 7 Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289-97.
- 8 Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-94.
- 9 Levesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002; 30: 440-9.
- 10 Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I, Levesque JP, Chappel J, Ross FP, Link DC. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005; 106: 3020-7.
- 11 Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996; 87: 1-13.
- 12 Fruehauf S, Tricot G. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes. Biol Blood Marrow Transplant 2010; 16: 1629-48.
- 13 Mendrone A Jr, Arrais CA, Saboya R, Chamone Dde A, Dulley FL. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci 2008; 39: 187-92.
- 14 Drake M, Ranaghan L, Morris TC, Nolan L, Desai ZR, Irvine AE, Jordan A, Magill K, Price S. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745-9.
- 15 Gandhi MK, Jestice K, Scott MA, Bloxham D, Bass G, Marcus RE. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9-13.
- 16 Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 2009; 41: 33-7.
- 17 Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet J, Montgomery P, Petersdorf S, Weiden P, Witherspoon R, Buckner CD. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-55.
- 18 Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-6.
- 19 Gianni AM. Where do we stand with respect to the use of peripheral blood progenitor cells? Ann Oncol 1994; 5: 781-4.
- 20 Yu J, Leisenring W, Bensinger WI, Holmberg LA, Rowley SD. The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion 1999; 39: 442-50.
- 21 Abrahamsen JF, Stamnesfet S, Liseth K, Hervig T, Bruserud O. Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells. Transfusion 2005; 45: 248-53.
- 22 Zubair AC, Rymer R, Young J, Keeton U, Befort R, Nolot B, Evans C, Bleach T, Torloni A. Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants. J Clin Apher 2009; 24: 6-11.
- 23 Fruehauf S, Ehninger G, Hubel K, Topaly J, Goldschmidt H, Ho AD, Muller S, Moos M, Badel K, Calandra G. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010; 45: 269-75.
- 24 Zubair AC, Kao G, Daley H, Schott D, Freedman A, Ritz J. CD34(+) CD38(−) and CD34(+) HLA-DR(−) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy 2006; 8: 399-407.
- 25 Prabhash K, Khattry N, Bakshi A, Karandikar R, Joshi A, Kannan S, Sastry PS, Parikh P, Kode JA. CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: potential predictor of early engraftment. Ann Oncol 2010; 21: 582-8.
- 26 Zubair AC, Grant R, Wu W, Tun H, Rivera C, Moreno-Aspitia A, Joyce M, Roy V, Colon-Otero G, Solberg LA. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion 2008; 48: 1106-14.
- 27 Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-26.
- 28 Christopherson K. W, 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004; 305: 1000-3.
- 29 Christopherson KW, Cooper S, Hangoc G, Broxmeyer HE. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol 2003; 31: 1126-34.
- 30 Prosper F, Vanoverbeke K, Stroncek D, Verfaillie CM. Primitive long-term culture initiating cells (LTC-ICs) in granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells have similar potential for ex vivo expansion as primitive LTC-ICs in steady state bone marrow. Blood 1997; 89: 3991-7.
- 31 Paz H, Wong CA, Li W, Santat L, Wong KK, Chatterjee S. Quiescent subpopulations of human CD34-positive hematopoietic stem cells are preferred targets for stable recombinant adeno-associated virus type 2 transduction. Hum Gene Ther 2007; 18: 614-26.
- 32 Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, Scadden DT. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000; 287: 1804-8.
- 33 Danova M, Porta C, Ferrari S, Brugnatelli S, Comolli G, Riccardi A, Ascari E. Cell cycle status and apoptosis of hematopoietic progenitor cells released into the peripheral blood after taxanes and granulocyte colony-stimulating factor in breast cancer patients. Oncol Rep 2000; 7: 585-9.
- 34 Jetmore A, Plett PA, Tong X, Wolber FM, Breese R, Abonour R, Orschell-Traycoff CM, Srour EF. Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients. Blood 2002; 99: 1585-93.
- 35 Zubair A, Zahrieh D, Daley H, Schott D, Gribben JG, Freedman A, Ritz J. Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion 2003; 43: 614-21.
- 36 Zubair AC, Zahrieh D, Daley H, Schott D, Gribben JG, Alyea EP, Schlossman R, Freedman A, Antin JH, Soiffer RJ, Neuberg D, Ritz J. Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion 2004; 44: 253-61.
Citing Literature
